← USPTO Patent Grants

Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof

Grant US12590168B2 Kind: B2 Mar 31, 2026

Assignee

Regeneron Pharmaceuticals, Inc.

Inventors

David DiLillo, Aynur Hermann, Jessica Kirshner, Kara Olson, Olga Sineshchekova, Eric Smith, Erica Ullman

Abstract

CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.

CPC Classifications

C07K 16/2818 C07K 16/2878 C07K 2317/565 C07K 2317/31 A61K 2039/505

Filing Date

2024-01-23

Application No.

18420588

Claims

35